Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
Open Access
- 29 April 2020
- Vol. 12 (5), 1125
- https://doi.org/10.3390/cancers12051125
Abstract
In recent years, the evolution of treatments has made it possible to significantly improve the outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular targeted therapies are effective in specific patient sub-groups, immune checkpoint inhibitors (ICIs) have greatly influenced the outcomes of a large proportion of NSCLC patients. While nivolumab activity was initially assessed irrespective of predictive biomarkers, subsequent pivotal studies involving other PD-1/PD-L1 inhibitors in pre-treated advanced NSCLC (atezolizumab within the OAK study and pembrolizumab in the Keynote 010 study) reported the first correlations between clinical outcomes and PD-L1 expression. However, PD-L1 could not be sufficient on its own to select patients who may benefit from immunotherapy. Many studies have tried to discover more precise markers that are derived from tumor tissue or from peripheral blood. This review aims to analyze any characteristics of the immunogram that could be used as a predictive biomarker for response to ICIs. Furthermore, we describe the most important genetic alteration that might predict the activity of immunotherapy.This publication has 183 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung CancerPLOS ONE, 2013
- Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array ProfilingThe American Journal of Pathology, 2011
- Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancerOncogene, 2011
- Subtle variations in Pten dose determine cancer susceptibilityNature Genetics, 2010
- The LKB1–AMPK pathway: metabolism and growth control in tumour suppressionNature Reviews Cancer, 2009
- Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung NeoplasmsThe Annals of Thoracic Surgery, 2009
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefitProceedings of the National Academy of Sciences of the United States of America, 2008
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences of the United States of America, 1971